1. Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices 
Rafael Romero-castro, Manuel Jimenez-saenz, Francisco Pellicer-bautista, Manuel Gomez-parra, Federico Argüelles Arias, Maria D. Guerrero-aznar, Angel Sendon-perez, Juan M. Herrerias-gutierrez 
Clinical Gastroenterology and Hepatology 
Volume 2, Issue 1, Pages (January 2004)
DOI: /S (03)

2. Figure 1
Outcome of averages of prothrombin time values (in seconds) when the patients started to bleed (time zero), immediately before rFVIIa treatment, and 30 minutes and 24 and 48 hours after its administration.
Clinical Gastroenterology and Hepatology 2004 2, 78-84DOI: ( /S (03) )

3. Figure 2
(A) Spurting bleeding from esophageal varices despite treatment with somatostatin. (B) A yellowish thrombus is formed afteradministration of rFVIIa and sclerotherapy with polidocanol with permanent hemostasis. (C) The hemostatic yellow plug persists 5 days after rFVIIa administration.
Clinical Gastroenterology and Hepatology 2004 2, 78-84DOI: ( /S (03) )

4. Figure 3
Mechanism of action of factor VII. F, factor; TF, tissue factor.
Clinical Gastroenterology and Hepatology 2004 2, 78-84DOI: ( /S (03) )